Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups

被引:82
作者
Taieb, David [1 ]
Jha, Abhishek [2 ]
Treglia, Giorgio [3 ,4 ,5 ,6 ]
Pacak, Karel [2 ]
机构
[1] Aix Marseille Univ, CERIMED, La Timone Univ Hosp, Dept Nucl Med, Marseille, France
[2] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Med Neuroendocrinol, NIH, Bethesda, MD 20892 USA
[3] Ente Osped Cantonale, Clin Nucl Med, Bellinzona, Switzerland
[4] Ente Osped Cantonale, PET CT Ctr, Bellinzona, Switzerland
[5] Lausanne Univ Hosp, Dept Nucl Med & Mol Imaging, Lausanne, Switzerland
[6] Ente Osped Cantonale, Gen Directorate, Hlth Technol Assessment Unit, Bellinzona, Switzerland
基金
美国国家卫生研究院;
关键词
pheochromocytoma; paraganglioma; PPGL; succinate dehydrogenase complex; SDHB; F-18-FDOPA; Ga-68-DOTATATE; F-18-FDG; I-131-MIBG; peptide receptor radionuclide therapy; theranostics; somatostatin receptor; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS; ALPHA-PARTICLE THERAPY; METASTATIC PHEOCHROMOCYTOMA; MALIGNANT PHEOCHROMOCYTOMA; GERMLINE MUTATIONS; GA-68-DOTATATE PET/CT; BONE METASTASES; HIGH-FREQUENCY; FOLLOW-UP; SDHB;
D O I
10.1530/ERC-19-0165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In recent years, advancement in genetics has profoundly helped to gain a more comprehensive molecular, pathogenic, and prognostic picture of pheochromocytomas and paragangliomas (PPGLs). Newly discovered molecular targets, particularly those that target cell membranes or signaling pathways have helped move nuclear medicine in the forefront of PPGL precision medicine. This is mainly based on the introduction and increasing experience of various PET radiopharmaceuticals across PPGL genotypes quickly followed by implementation of novel radiotherapies and revised imaging algorithms. Particularly, Ga-68-labeled-SSAs have shown excellent results in the diagnosis and staging of PPGLs and in selecting patients for PRRT as a potential alternative to I-123/131-MIBG theranostics. PRRT using Y-90/Lu-177-DOTA-SSAs has shown promise for treatment of PPGLs with improvement of clinical symptoms and/or disease control. However, more well-designed prospective studies are required to confirm these findings, in order to fully exploit PRRT's antitumoral properties to obtain the final FDA approval. Such an approval has recently been obtained for high-specific-activity I-131-MIBG for inoperable/metastatic PPGL. The increasing experience and encouraging preliminary results of these radiotherapeutic approaches in PPGLs now raises an important question of how to further integrate them into PPGL management (e.g. mon otherapy or in combination with other systemic therapies), carefully taking into account the PPGLs locations, genotypes, and growth rate. Thus, targeted radionuclide therapy (TRT) should preferably be performed at specialized centers with an experienced interdisciplinary team. Future perspectives include the introduction of dosimetry and biomarkers for therapeutic responses for more individualized treatment plans, alpha-emitting isotopes, and the combination of TRT with other systemic therapies.
引用
收藏
页码:R627 / R652
页数:26
相关论文
共 156 条
[1]   Genetic testing in pheochromocytoma or functional paraganglioma [J].
Amar, L ;
Bertherat, J ;
Baudin, E ;
Ajzenberg, C ;
Bressac-de Paillerets, B ;
Chabre, O ;
Chamontin, B ;
Delemer, B ;
Giraud, S ;
Murat, A ;
Niccoli-Sire, P ;
Richard, SP ;
Rohmer, V ;
Sadoul, JL ;
Strompf, L ;
Schlumberger, M ;
Bertagna, X ;
Plouin, PF ;
Jeunemaitre, X ;
Gimenez-Roqueplo, AP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8812-8818
[2]   Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas [J].
Amar, Laurence ;
Baudin, Eric ;
Burnichon, Nelly ;
Peyrard, Severine ;
Silvera, Stephane ;
Bertherat, Jerome ;
Bertagna, Xavier ;
Schlumberger, Martin ;
Jeunemaitre, Xavier ;
Gimenez-Roqueplo, Anne-Paule ;
Plouin, Pierre-Francois .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (10) :3822-3828
[3]   Prospective comparison of 68Ga-DOTATATE and 18F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases [J].
Archier, Aurelien ;
Varoquaux, Arthur ;
Garrigue, Philippe ;
Montava, Marion ;
Guerin, Carole ;
Gabriel, Sophie ;
Beschmout, Eva ;
Morange, Isabelle ;
Fakhry, Nicolas ;
Castinetti, Frederic ;
Sebag, Frederic ;
Barlier, Anne ;
Loundou, Anderson ;
Guillet, Benjamin ;
Pacak, Karel ;
Taieb, David .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (07) :1248-1257
[4]  
Ashwathanarayana AG, 2017, J NUCL MED TECHNOL, V45, P314, DOI 10.2967/jnmt.117.197400
[5]   Bone Metastases and Skeletal-Related Events in Patients With Malignant Pheochromocytoma and Sympathetic Paraganglioma [J].
Ayala-Ramirez, Montserrat ;
Palmer, J. Lynn ;
Hofmann, Marie-Claude ;
de la Cruz, Maxine ;
Moon, Bryan S. ;
Waguespack, Steven G. ;
Habra, Mouhammed Amir ;
Jimenez, Camilo .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (04) :1492-1497
[6]   Clinical Risk Factors for Malignancy and Overall Survival in Patients with Pheochromocytomas and Sympathetic Paragangliomas: Primary Tumor Size and Primary Tumor Location as Prognostic Indicators [J].
Ayala-Ramirez, Montserrat ;
Feng, Lei ;
Johnson, Marcella M. ;
Ejaz, Shamim ;
Habra, Mouhammed Amir ;
Rich, Thereasa ;
Busaidy, Naifa ;
Cote, Gilbert J. ;
Perrier, Nancy ;
Phan, Alexandria ;
Patel, Shreyaskumar ;
Waguespack, Steven ;
Jimenez, Camilo .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (03) :717-725
[7]   Molecular Pathways: Targeted α-Particle Radiation Therapy [J].
Baidoo, Kwamena E. ;
Yong, Kwon ;
Brechbiel, Martin W. .
CLINICAL CANCER RESEARCH, 2013, 19 (03) :530-537
[8]  
Basu Sandip, 2016, World J Nucl Med, V15, P38, DOI 10.4103/1450-1147.165353
[9]  
Baum Richard P, 2018, Oncotarget, V9, P16932, DOI 10.18632/oncotarget.24524
[10]   Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes [J].
Benn, DE ;
Gimenez-Roqueplo, AP ;
Reilly, JR ;
Bertherat, J ;
Burgess, J ;
Byth, K ;
Croxson, M ;
Dahia, PLM ;
Elston, M ;
Gimm, O ;
Henley, D ;
Herman, P ;
Murday, V ;
Niccoli-Sire, P ;
Pasieka, JL ;
Rohmer, V ;
Tucker, K ;
Jeunemaitre, X ;
Marsh, DJ ;
Plouin, PF ;
Robinson, BG .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (03) :827-836